MAIA Bio (MAIA): Long-Term Debt to Capital Ratio

MAIA Biotechnology - graphic logo of issuer MAIA

Environmental compliance and the digitalization of archives set the development vector for MAIA Biotechnology. Monitoring the long-term debt-to-equity ratio confirms the sustainability of this strategy, while the value of 0.00 characterizes this level. Innovations in the THIO platform for combating tumors require massive expenditures, and the clinical success of the drugs determines the future protection of the business until final tests are completed.

MAIA - MAIA Biotechnology Long-Term Debt to Equity over the range 04/28/2023 - 10/28/2026

MAIA Biotechnology (MAIA) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Price MAIA Biotech|MAIA - Price Target Chart
- market capitalization data:
Market Capitalization MAIA Biotechnology, Inc.|MAIA - Enterprise Value
- book capitalization data:
Accounting Value per Share MAIA Biotechnology|MAIA - Company Book Value|Market-to-Book Ratio MAIABiotech.com|MAIA - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity MAIA Biotechnology|MAIA - Long-Term Debt to Equity|Current Liabilities to Capital MAIABiotech.com|MAIA - Company Aggregate Debts|Debt to Net Assets MAIA Biotechnology, Inc.|MAIA - Company Long-Term Liabilities|Short-Term Debt MAIA Biotechnology
Fundamental company valuation:MAIA MAIA Biotech
Brand item of MAIA Biotechnology Inc

Professional asset selection requires rigorous filtering of debt loads. This ratio compares liabilities with maturities exceeding one year to equity to determine financial stability. For MAIA Biotechnology (MAIA), with its patent-protected THIO development, this balance is critical when funding R&D. A decrease in this metric confirms the safety of the liability structure. Monitoring the long-term debt-to-equity ratio allows for the timely detection of expansion stagnation.

Who MAIA Biotechnology competes with

Long-Term Liabilities to Capital IBRX|Long-Term Debt to Equity Immunocore PLC IMCR|Long-Term Debt to Capital Ratio Janux Corp (JANX)|Arcus Biosciences, Inc. - Long-Term Debt to Capital|zymeworks.com - Long-Term Debt to Equity Ratio|TNGX (Tango Therapeutics, Inc.) - Long-Term Debt to Equity|IOVA: Long-Term Liabilities to Capital|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity CMPX (Compass Therapeutics)|Long-Term Liabilities to Capital replimune.com|LYEL: Long-Term Debt to Capital|Long-Term Indebtedness to Equity Innate Pharma SA IPHA|PYXS: Long-Term Debt to Equity Ratio|CGEN - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio IO Biotech, Inc. (IOBT)|STRO - Long-Term Debt to Capital Coefficient|MiNK Therapeutics - Long-Term Debt to Capital|HOWL (Werewolf Therapeutics, Inc.) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity IMMX|Long-Term Debt to Equity Ratio ALXO|Long-Term Debt to Equity CUE (Cue Biopharma)|Long-Term Debt to Equity Ratio pdsbiotech.com PDSB|Long-Term Debt to Equity Ratio SONN (Sonnet BioTherapeutics Holdings)|Liminatus Pharma Inc. - Long-Term Debt to Capital|Lava Tx (LVTX) - Long-Term Debt to Equity|NXTC: Long-Term Debt to Capital Ratio|Long-Term Debt to Equity LPTX|Long-Term Liabilities to Capital Intensity Therapeutics, Inc.|Sensei Biotherapeutics Inc - Long-Term Debt to Equity Ratio|Long-Term Indebtedness to Equity Theriva Biologics Inc (TOVX)|Long-Term Debt to Equity Ratio Gritstone bio, Inc.|Long-Term Loans to Capital Ratio Kineta Corp (KA)|Long-Term Debt to Capital NexImmune, Inc.|Long-Term Debt to Capital Coefficient Turnstone Biologics Corp TSBX|VCNX (Vaccinex) - Long-Term Debt to Capital|HARP: Long-Term Liabilities to Capital